Surgical management and outcome of primary intracranial Rosai-Dorfman disease: a single-institute experience and pooled analysis of individual patient data
Authors:
- 27 March 2023
- journal article
- research article
- Published by Springer Nature in Neurosurgical Review
- Vol. 46 (1) , 1-15
Abstract
Primary intracranial Rosai-Dorfman disease (PIRDD) is considered a nonmalignant nonneoplastic entity, and the outcome is unclear due to its rarity. The study aimed to elaborate the clinic-radiological features, treatment strategies, and progression-free survival (PFS) in patients with PIRDD. Patients with pathologically confirmed PIRDD in our institute were reviewed. Literature of PIRDD, updated until December 2019, was systematically searched in 7 databases (Embase, PubMed, Cochrane database, Web of Science, Wanfang Data Knowledge Service Platform, the VIP Chinese Science and Technology Periodical Database (VIP), and the China National Knowledge Infrastructure (CNKI)). These prior publication data were processed and used according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Clinical-radiological characteristics and adverse factors for PFS were evaluated in the pooled cohort. The pooled cohort of 124 cases (81 male and 43 female), with a mean age of 39.7 years, included 11 cases from our cohort and 113 cases from 80 prior studies. Twenty-nine patients (23.4%) had multiple lesions. Seventy-four patients (59.7%) experienced gross total resection (GTR), 50 patients (40.3%) had non-GTR, 15 patients (12.1%) received postoperative adjuvant radiation, and 23 patients (18.5%) received postoperative steroids. A multivariate Cox regression revealed that GTR (HR = 4.52; 95% CI 1.21–16.86; p = 0.025) significantly improved PFS, and multiple lesions (p = 0.060) tended to increase the hazard of recurrence. Neither radiation (p = 0.258) nor steroids (p = 0.386) were associated with PFS. The overall PFS at 3, 5, and 10 years in the pooled cohort was 88.4%, 79.4%, and 70.6%, respectively. The PFS at 5 and 10 years in patients with GTR was 85.4% and 85.4%, respectively, which was 71.5% and 35.8%, respectively, in patients without GTR. Gross total resection significantly improved PFS and was recommended for PIRDD. Radiation and steroids were sometimes empirically administered for residual, multiple, or recurrent PIRDD, but the effectiveness remained arguable and required further investigation. Systematic review registration number: CRD42020151294.Keywords
This publication has 49 references indexed in Scilit:
- Rosai-Dorfman disease isolated to the central nervous system: A report of six casesNeuropathology, 2010
- Therapeutic use of Rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai‐Dorfman disease)American Journal of Hematology, 2007
- Regression of intracranial Rosai–Dorfman disease following corticosteroid therapyJournal of Neurosurgery, 2006
- Extranodal Sinus Histiocytosis (Rosai-Dorfman Disease) of the brain parenchymaActa Neurochirurgica, 2003
- Intracranial Rosai—Dorfman disease treated with microsurgical resection and stereotactic radiosurgeryJournal of Neurosurgery, 2003
- Rosai-Dorfman Disease Isolated to the Central Nervous System: A Report of 11 CasesLaboratory Investigation, 2001
- Rosai—Dorfman disease presenting multiple intracranial lesions with unique findings on magnetic resonance imagingJournal of Neurosurgery, 1999
- Rosai-Dorfman Disease Mimicking Multiple MeningiomaNeurosurgery, 1995
- Isolated extranodal intracranial sinus histiocytosis in a 5-year-old boyJournal of Neurosurgery, 1993
- Sinus histiocytosis with massive lymphadenopathyJournal of the American Academy of Dermatology, 1988